DAWN Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Day One Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.62 |
| 52 Week High | US$18.07 |
| 52 Week Low | US$11.30 |
| Beta | -1.52 |
| 11 Month Change | -8.77% |
| 3 Month Change | -0.44% |
| 1 Year Change | 14.74% |
| 33 Year Change | -25.00% |
| 5 Year Change | n/a |
| Change since IPO | -47.39% |
Recent News & Updates
Recent updates
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Shareholder Returns
| DAWN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | -7.5% | -1.2% |
| 1Y | 14.7% | 14.1% | 30.4% |
Return vs Industry: DAWN matched the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: DAWN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DAWN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DAWN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 174 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
Day One Biopharmaceuticals, Inc. Fundamentals Summary
| DAWN fundamental statistics | |
|---|---|
| Market cap | US$1.36b |
| Earnings (TTM) | -US$84.29m |
| Revenue (TTM) | US$101.95m |
13.5x
P/S Ratio-16.3x
P/E RatioIs DAWN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAWN income statement (TTM) | |
|---|---|
| Revenue | US$101.95m |
| Cost of Revenue | US$2.30m |
| Gross Profit | US$99.66m |
| Other Expenses | US$183.95m |
| Earnings | -US$84.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 97.75% |
| Net Profit Margin | -82.68% |
| Debt/Equity Ratio | 0% |
How did DAWN perform over the long term?
See historical performance and comparison